Stockscreener 앱 받기
123.95
4.70%
5.56
시간 외 거래:
123.95
Revvity Inc 주식(RVTY)의 최신 뉴스
Raymond James Lowers Revvity (NYSE:RVTY) Price Target to $140.00 - MarketBeat
Revvity Inc (RVTY) Shares Up 3.21% on Jan 21 - GuruFocus.com
Lentiviral Vectors Market Generated Opportunities, Future - openPR
Avanza Fonder AB Invests $898,000 in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Oak Thistle LLC Purchases Shares of 2,842 Revvity, Inc. (NYSE:RVTY) - MarketBeat
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test - MSN
Stocks Showing Improved Relative Strength: Revvity - MSN
Revvity, Inc. (NYSE:RVTY) Shares Purchased by Contravisory Investment Management Inc. - MarketBeat
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Ex-Dividend Reminder: Revvity, Dime Community Bancshares and McGrath RentCorp - Nasdaq
Revvity’s Q4 2024 Earnings: What to Expect - Nasdaq
Neurogenomics Market Forecast and Trends Analysis to 2031: Healthcare Investments and Early Detection Drive Robust Uptake of Neurogenomics Solutions - GlobeNewswire Inc.
Revvity’s Q4 2024 Earnings: What To Expect - Barchart
Revvity to Seek M&A -January 13, 2025 at 11:15 am EST - Marketscreener.com
Revvity’s $1.5 Billion Syndicated Revolving Credit Facility - Global Legal Chronicle
Revvity (NYSE:RVTY) Shares Gap UpHere's What Happened - MarketBeat
Revvity to Announce Q4 and Full-Year 2024 Results - TipRanks
Revvity Partners with Element Biosciences to Transform Neonatal Genetic Testing - StockTitan
Revvity Announces FDA Clearance for First Automated Free Testosterone Test - Technology Networks
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance - Business Wire
Revvity wins FDA clearance for ChLIA assay in free testosterone measurement - MSN
Revvity Wins FDA Nod for Automated Free Testosterone Test - MPO-mag
Bernstein revises Revvity stock outlook—can stability outweigh slowing growth? - Investing.com Nigeria
Revvity gets FDA clearance for first automated free testosterone test - MSN
Revvity (NYSE:RVTY) Downgraded by Sanford C. Bernstein to "Market Perform" - MarketBeat
Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone Test -January 10, 2025 at 08:00 am EST - Marketscreener.com
Bernstein revises Revvity stock outlook—can stability outweigh slowing growth? By Investing.com - Investing.com South Africa
RVTYRevvity, Inc. Latest Stock News & Market Updates - StockTitan
Revvity Secures FDA Clearance for First-Ever Automated Free Testosterone Test - StockTitan
Revvity (FRA:PKN) Earnings Yield (Joel Greenblatt) % : 1.99% (As of Sep. 2024) - GuruFocus.com
No time to waste: Revvity CFO Max Krakowiak - CFO.com
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity, Inc. (NYSE:RVTY) Insider Tajinder S. Vohra Sells 5,492 Shares - MarketBeat
Revvity secures new $1.5 billion credit facility By Investing.com - Investing.com Canada
Revvity, Inc. (RVTY) Secures New $1.5 Billion Unsecured Revolvin - GuruFocus.com
Revvity secures new $1.5 billion credit facility - Investing.com
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Shareholders Should Be Pleased With Revvity, Inc.'s (NYSE:RVTY) Price - Simply Wall St
Revvity, Inc. (NYSE:RVTY) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Revvity, Inc. (NYSE:RVTY) Shares Sold by Everence Capital Management Inc. - MarketBeat
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN
Revvity (FRA:PKN) Float Percentage Of Total Shares Outstanding : 75.15% (As of Dec. 30, 2024) - GuruFocus.com
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
(RVTY) Proactive Strategies - Stock Traders Daily
Is Revvity Stock Underperforming the S&P 500? - Nasdaq
2.28%
자본화:
|
볼륨(24시간):